First, our findings suggest that clinical trials treating breast cancer with lapatinib in combination with AKT (e.g., NCT01245205) or PI3K inhibitors (e.g., NCT01471847 and NCT01589861) should pay careful attention to PIK3CA status, as our data predicts patients with PIK3CA mutations are most likely to benefit from such combination treatment regimes. This evidence concerns the gene AKT1 and breast cancer.